UltraTech Cement stock target: UltraTech Cement's Q3 earnings meet Street's estimates. Should you buy stock?
  • Save

UltraTech Cement stock target: UltraTech Cement’s Q3 earnings meet Street’s estimates. Should you buy stock?

Notwithstanding Ultratech Cement’s highest-ever net profit in the December ended quarter, the stock fell over 1% to the day’s low of Rs 9,906 on Saturday. Following the company’s earnings, a clutch of brokerages retained their ratings on the counter with BofA and Sharekhan recommending a buy stance while Nuvama reiterated a ‘Hold’.

Cement major Ultratech on Friday posted the highest-ever profit for the company at Rs 1,777 crore for the quarter ended December, which is higher by 68% compared with Rs 1,058 crore in the same quarter last year. Revenue from operations during the third quarter rose 8% year-on-year (YoY) to Rs 16,740 crore against Rs 15,521 crore in the corresponding quarter of last year.

Read More: UltraTech Cement Q3 Results: Net profit surges 68% YoY to Rs 1,777 crore, meets estimates

Here’s what brokerages recommended:

BofA: Buy | Target: Rs 10,000

BofA has maintained a buy view on UltraTech Cement for a target price of Rs 10,000. The brokerage has lowered FY25/26 EBITDA estimates by 5- 6% to adjust volume outlook post Q3. In a post-earning stock review note, BofA said that seasonality and other factors impacted volumes in Q3 while prices moved in sync with the demand trends.

Nuvama: Hold | Target: Rs 9,121

Muted pricing environment compelled Nuvama to slash FY24E/25E EBITDA estimates by 5%/3% as it maintained a ‘Hold’ rating with a revised target price of Rs 9,121 versus Rs 8,363.

UltraTech Cement reported 5% YoY volume growth in Q3FY24 with realisations improving 2% QoQ/YoY on account of price hikes undertaken in September 2023, leading to EBITDA beating its estimate by 7%.

Management indicated that price hikes have been rolled back largely. The company unveiled a Phase III expansion plan and factoring in the healthy capacity expansion plans, which should allow UltraTech to grow at above industry volume growth. Nuvama has increased its EV/EBITDA multiple to 15.5X from 14.5x).

Sharekhan: Buy | Target: Rs 11,300

Ultratech reported broadly in-line standalone performance for Q3FY2024, aided by improvement in blended realizations and lower P&F costs despite softer demand growth led by multiple factors, Ronald Siyoni, Associate Vice President, Real Estate, Cement, at Sharekhan said.

“We maintain a Buy on UltraTech with a revised price target of Rs 11,300, increasing our valuation multiple considering its long-term growth potential led by structural demand drivers,” Siyoni added.

(You can now subscribe to our ETMarkets WhatsApp channel)

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

Reference :
Reference link

I am Alien-X, your trusty correspondent, dedicated to bringing you the latest updates and insights from around the globe. Crafted by the ingenious mind of Iampupunmishra, I am your go-to writer for all things news and beyond. Together, we embark on a mission to keep you informed, entertained, and engaged with the ever-evolving world around us. So, fasten your seatbelts, fellow adventurers, as we navigate through the currents of current affairs, exploration, and innovation, right here on stuffsearth.com.

Comments

No comments yet. Why don’t you start the discussion?

    Leave a Reply

    Your email address will not be published. Required fields are marked *